A lawyer for the U.S. Chamber of Commerce on Friday urged a federal judge to block President Joe Biden's administration from implementing a new program that would let Medicare negotiate prices with ...
The Chamber of Commerce urged a federal judge on Friday to stop the new Medicare drug price negotiation program before Oct. 1 ...
The Southern District Court of Ohio on Friday heard oral arguments from the federal government and the Chamber of Commerce in the latter’s lawsuit challenging the Medicare Drug Price ...
Drug companies challenging the law in court could still have several chances to stop the program before next year's election.
“Congress knew that withdrawing all products from federal healthcare programs would be economic suicide—not a ‘real option.’” – U.S. Chamber motion for preliminary injunction On August ...
One Republican mocked Medicare drug price negotiation as “godfather mafia-style” policy, saying it lets the government steal ...
All of the companies had drugs that made the list of the first 10 medications to be subject to Medicare price negotiations. PhRMA, a leading drug industry trade group, and the US Chamber of ...
One year after IRA passage, bad actors try to thwart drug price negotiation, and Biden’s efforts to defend it fall short. Merck is suing the federal government over a plan to negotiate Medicare drug ...
Aug 31 (Reuters) - Drugmakers challenging a Biden administration program requiring them to negotiate with Medicare over the prices of selected costly drugs may not have a clear legal precedent on ...
Judge Thomas M. Rose of the U.S. District Court for the Southern District of Ohio has withdrawn from a case that could block Medicare's historic drug price negotiation program. Rose disclosed that ...
The Biden administration has picked the first 10 high-priced prescription drugs subject to federal price negotiations, taking a swipe at the powerful pharmaceutical industry. It marks a major ...
Japanese drugmaker Astellas (OTCPK:ALPMF) has withdrawn a federal lawsuit that challenged the US government’s right to negotiate drug prices for its Medicare program, but maintained the newly ...
